Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma

NCT00602511 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Bortezomib
DRUG: Thalidomide

Sponsor

Nordic Myeloma Study Group